



Correction to: Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study

Hiroshi Hagino¹ · Akinori Sakai² · Satoshi Ikeda³ · Yasuo Imanishi⁴ · Hiroshi Tsurukami⁵ · Satoru Nakajo⁶ · Naohisa Miyakoshi⁷

Published online: 27 July 2019

© The Japanese Society Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2019

Correction to: Journal of Bone and Mineral Metabolism
<https://doi.org/10.1007/s00774-019-01005-z>

In the original publication of the article, the Figures 2 and 3 were published incorrectly. The corrected Figs. 2 and 3 are given below.




Fig. 2 Mean percent change (95% CI) from baseline to 12 months in, **a** lumbar spine (L1–L4) and **b** total hip BMD, **c** responder rate in the IV IBN (FAS). BMD bone mineral density, CI confidence interval, FAS full analysis set, IV IBN intravenous ibandronate group. * p value < 0.0001

The original article can be found online at <https://doi.org/10.1007/s00774-019-01005-z>.

✉ Hiroshi Hagino
hagino@tottori-u.ac.jp

¹ School of Health Science, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago 683-8503, Tottori, Japan

² Department of Orthopedic Surgery, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan

³ Department of Orthopedic Surgery, Ken-Ai Memorial Hospital, Onga, Fukuoka, Japan

⁴ Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan

⁵ Tsurukami Clinic of Orthopedics and Rheumatology, Tamana, Kumamoto, Japan

⁶ Nakajou Orthopedic Clinic, Sendai, Miyagi, Japan

⁷ Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Akita, Japan




Fig. 3 Mean percent change from baseline to 12 months in lumbar spine BMD according to patient characteristics and comorbidity in IV IBN and OBP. 25-OH-VD₃ 25-hydroxyvitamin D₃, BMD bone mineral density, CI confidence interval, eGFR estimated glomerular filtration rate, IV IBN intravenous ibandronate group, OBP oral bisphosphonate group

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.